211 related articles for article (PubMed ID: 8971168)
1. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
[TBL] [Abstract][Full Text] [Related]
2. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
Kreitman RJ; Puri RK; Pastan I
Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
[TBL] [Abstract][Full Text] [Related]
3. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma.
Puri RK
Toxicol Pathol; 1999; 27(1):53-7. PubMed ID: 10367674
[TBL] [Abstract][Full Text] [Related]
4. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity.
Puri RK; Leland P; Obiri NI; Husain SR; Mule J; Pastan I; Kreitman RJ
Cell Immunol; 1996 Jul; 171(1):80-6. PubMed ID: 8660841
[TBL] [Abstract][Full Text] [Related]
5. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.
Leland P; Taguchi J; Husain SR; Kreitman RJ; Pastan I; Puri RK
Mol Med; 2000 Mar; 6(3):165-78. PubMed ID: 10965493
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
Beseth BD; Cameron RB; Leland P; You L; Varricchio F; Kreitman RJ; Maki RA; Jablons DM; Husain SR; Puri RK
Ann Thorac Surg; 2004 Aug; 78(2):436-43; discussion 436-43. PubMed ID: 15276492
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.
Rand RW; Kreitman RJ; Patronas N; Varricchio F; Pastan I; Puri RK
Clin Cancer Res; 2000 Jun; 6(6):2157-65. PubMed ID: 10873064
[TBL] [Abstract][Full Text] [Related]
8. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein.
Puri RK; Leland P; Kreitman RJ; Pastan I
Int J Cancer; 1994 Aug; 58(4):574-81. PubMed ID: 8056454
[TBL] [Abstract][Full Text] [Related]
9. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy.
Husain SR; Behari N; Kreitman RJ; Pastan I; Puri RK
Cancer Res; 1998 Aug; 58(16):3649-53. PubMed ID: 9721874
[TBL] [Abstract][Full Text] [Related]
10. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin.
Puri RK; Debinski W; Obiri N; Kreitman R; Pastan I
Cell Immunol; 1994 Apr; 154(1):369-79. PubMed ID: 8131209
[TBL] [Abstract][Full Text] [Related]
11. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein.
Joshi BH; Leland P; Silber J; Kreitman RJ; Pastan I; Berger M; Puri RK
Br J Cancer; 2002 Jan; 86(2):285-91. PubMed ID: 11870521
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.
Kawakami M; Kawakami K; Puri RK
J Neurooncol; 2003 Oct; 65(1):15-25. PubMed ID: 14649882
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo studies of antitumor effects of the recombinant immunotoxin MSH-PE38KDEL on melanoma.
Hui Q; Ma J; Song J; Liu Z; Ren H; Jiang W; Wang Y; Xu Y; Guo D; Zhang X; Lu S
Neoplasma; 2014; 61(4):392-400. PubMed ID: 25027740
[TBL] [Abstract][Full Text] [Related]
14. Cintredekin besudotox in treatment of malignant glioma.
Mut M; Sherman JH; Shaffrey ME; Schiff D
Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792
[TBL] [Abstract][Full Text] [Related]
15. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.
Husain SR; Gill P; Kreitman RJ; Pastan I; Puri RK
Mol Med; 1997 May; 3(5):327-38. PubMed ID: 9205948
[TBL] [Abstract][Full Text] [Related]
17. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
Kreitman RJ; Hansen HJ; Jones AL; FitzGerald DJ; Goldenberg DM; Pastan I
Cancer Res; 1993 Feb; 53(4):819-25. PubMed ID: 8428363
[TBL] [Abstract][Full Text] [Related]
18. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.
Joshi BH; Leland P; Asher A; Prayson RA; Varricchio F; Puri RK
Cancer Res; 2001 Nov; 61(22):8058-61. PubMed ID: 11719427
[TBL] [Abstract][Full Text] [Related]
19. A chimeric protein comprised of IL-4 and Pseudomonas exotoxin is cytotoxic for activated human lymphocytes.
Puri RK; Mehrotra PT; Leland P; Kreitman RJ; Siegel JP; Pastan I
J Immunol; 1994 Apr; 152(7):3693-700. PubMed ID: 8144944
[TBL] [Abstract][Full Text] [Related]
20. A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin.
Debinski W; Puri RK; Kreitman RJ; Pastan I
J Biol Chem; 1993 Jul; 268(19):14065-70. PubMed ID: 8314773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
